An Open-Label, Multicentre Pilot Study of Bosentan in Pulmonary Arterial Hypertension Related to Congenital Heart Disease
BACKGROUND: Bosentan has been shown to be a safe and efficacious treatment for idiopathic pulmonary arterial hypertension (PAH) and PAH associated with connective tissue disease. However, there are limited studies examining the benefits of bosentan in PAH associated with congenital heart disease (CH...
Main Authors: | Reda Ibrahim, John T Granton, Sanjay Mehta |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2006-01-01
|
Series: | Canadian Respiratory Journal |
Online Access: | http://dx.doi.org/10.1155/2006/746176 |
Similar Items
-
Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease
by: Rui Baptista, et al.
Published: (2013-02-01) -
Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease
by: Rui Baptista, et al.
Published: (2013-02-01) -
Review of bosentan in the management of pulmonary arterial hypertension
by: Eli Gabbay, et al.
Published: (2008-01-01) -
Improved low-risk criteria scores for combination therapy of sildenafil and generic bosentan in patients with congenital heart disease with severe pulmonary hypertension: A prospective open label study
by: Kritvikrom Durongpisitkul, et al.
Published: (2021-01-01) -
Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan
by: Mark J Schuuring, et al.
Published: (2010-08-01)